Clinical Trials Directory

Trials / Unknown

UnknownNCT02342028

The Number and Function of Regular T Cell in Patients With Obstructive Sleep Apnea

Impact of Intermittent Hypoxia on the Number and Function of Regular T Cell in Patients With Obstructive Sleep Apnea

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Taipei Veterans General Hospital, Taiwan · Other Government
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Accepted

Summary

To compare the number and function of regular T cell of patients with obstructive sleep apnea (OSA) versus that of age-, gender- and BMI (body mass index)-matched controls

Detailed description

Patients with obstructive sleep apnea (OSA) experience intermittent hypoxemia and arousal during sleep due to recurrent collapse of upper airway. Epidemiologic evidence showed they were at higher risk for autoimmune diseases. The regular T cell (Treg) has a crucial role in controlling autoimmunity. In this study, 40 OSA patients and 40 age-, gender- and BMI-matched controls will be recruited. Peripheral venous blood of the participants is drawn for numeration of CD4+CD25+FoxP3+ regular T cells by flow cytometry. As well, the CD4+CD25+ regular T cells are enriched by MACS and tested for their suppressive functions on proliferation assays. Th12+ CD4+ cells are also measured.

Conditions

Interventions

TypeNameDescription
BIOLOGICALOSAThis study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.

Timeline

Start date
2015-01-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2015-01-19
Last updated
2015-01-26

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT02342028. Inclusion in this directory is not an endorsement.